Returning Genome and Metabolome Data to FinTerveys 2017 Participants: P5.fi FinTerveys Study

Returning Genome and Metabolome Data to FinTerveys 2017 Participants: P5.fi

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03650127

Acronym

Enrollment

3449

Registered

2018-08-28

Start date

2018-02-02

Completion date

2023-12-31

Last updated

2021-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease, Deep Vein Thrombosis, Type 2 Diabetes

Keywords

Genetic risk score, metabolic risk score, health promotion, web-based, intervention

Brief summary

P5.fi study - P4 together with a fifth 'P' and '.fi' for population health Finally Implemented in Finland - studies the value of returning genetic and metabolomic risk information in two diseases (coronary heart disease and type 2 diabetes) and one feature (venous thromboembolism). The hypothesis of the study is that 1) combining genetic and metabolic risk with traditional risk factors adds value to the personal risk assessment of these diseases, 2) such risk information can be provided to individuals using a web based user portal in an easily understandable and useful format, and 3) receiving genetic and metabolomic risk information has an effect on the health of the study participants. The study is a continuation of FinHealth 2017 -study, which involved more than 7,000 Finns from around the country. The participants of FinHealth were invited to participate in P5.fi -study. The new research utilises information, samples, and measurements obtained in the FinHealth Study. Prospective clinical significance of selected genetic and metabolomic risk scores will be studied in 30.000 Finnish individuals. The study will analyze the genetic and metabolomic profile of the P5.fi participants and develop and test a protocol for returning them health related risk information. The impact of the intervention will by followed up by questionnaires and national health registers for five years.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

\- Only participants of FinHealth 2017 -study are eligible for the study

Exclusion criteria

\- Participants not part of FinHealth 2017 -study are not eligible

Design outcomes

Primary

Measure	Time frame	Description
Coronary heart disease/Type 2 diabetes/Venous thromboembolism diagnosis	Measure is assessed after a year from the start of the study.	Disease diagnosis observed from the national hospitalization and death registries.

Countries

Finland

Outcome results